ALLO Allogene Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Allogene Therapeutics, Inc. (ALLO) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 12, 2026, a 10-Q quarterly report filed on May 13, 2026, an 8-K current report filed on June 22, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Allogene Therapeutics, Inc. (ALLO) (SEC CIK 1737287), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Allogene Therapeutics, Inc.
Ask AI about ALLO filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting ALLO positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on ALLO.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Allogene Therapeutics, Inc. (ALLO) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Profitability | |||
| Revenue | $95K | $22K | $0 |
| Operating Income | -$327.7M | -$273.2M | -$209.3M |
| Net Income | -$1.6B | -$257.6M | -$190.9M |
| Op. Margin | -344986.3% | -1241813.6% | - |
| Net Margin | -1644421.1% | -1170863.6% | - |
| Balance Sheet | |||
| Total Assets | - | $548.7M | $415.9M |
| Equity | - | $422.2M | $292.5M |
| ROE | - | -61.0% | -65.3% |
| Per Share | |||
| EPS | - | $-1.32 | $-0.87 |
| Cash Flow | |||
| Operating CF | - | -$200.3M | -$149.2M |
| CapEx | $1.5M | $694K | $386K |
Source: XBRL financial data from Allogene Therapeutics, Inc. (ALLO) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jun 22, 2026 | - | - | - |
8-K | May 28, 2026 | - | - | |
8-K | May 13, 2026 | - | - | |
10-Q | May 13, 2026 | Mar 31, 2026 | - | |
8-K | Apr 15, 2026 | - | - | - |
8-K | Apr 13, 2026 | - | - | - |
8-K | Apr 13, 2026 | - | - | - |
10-K | Mar 12, 2026 | Dec 31, 2025 | - | |
8-K | Mar 12, 2026 | - | Analysis | - |
10-Q | Nov 6, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | - | |
10-Q | May 13, 2025 | Mar 31, 2025 | - | |
10-K | Mar 13, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | - | |
SC 13G | Nov 4, 2024 | - | - | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | - | |
10-Q | May 13, 2024 | Mar 31, 2024 | - | |
10-K | Mar 14, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | - | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | - | |
SC 13G | Jul 10, 2023 | - | - | |
10-Q | May 3, 2023 | Mar 31, 2023 | - | |
10-K | Feb 28, 2023 | Dec 31, 2022 | - | |
SC 13G | Feb 13, 2023 | - | - | |
SC 13G | Feb 9, 2023 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate ALLO share value held by 13F filers tracked by SignalX, by quarter.
- State Street Corp+5.90M (+214%)
- Two Sigma Investments+1.95M (+57%)
- D.E. Shaw & Co+1.48M (+115%)
- Millennium Management+1.48M (+80%)
- BlackRock+1.42M (+8%)
- Citadel Advisors LLC5.32M (-44%)
- Citigroup238.6K (-40%)
- Wells Fargo & Co111.1K (-55%)
- Renaissance Technologies LLC47.8K (-2%)
- BNY Mellon10.7K (-3%)
- Ameriprise Financial+244.6K
- Prudential Financial+25.0K
- PNC Financial Services+3.1K
- U.S. Bancorp+572
- Vanguard Group Inc−9.25M
- JPMorgan Chase & Co−979.1K
- Invesco Ltd−609.8K
- StoneX Group Inc.−14.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 167 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest ALLO SEC filings in 2026?
Allogene Therapeutics, Inc. (ALLO) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on May 13, 2026, an 8-K current report on June 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ALLO file its most recent 10-K annual report?
Allogene Therapeutics, Inc. (ALLO) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ALLO 10-Q quarterly reports?
Allogene Therapeutics, Inc. (ALLO)'s most recent 10-Q quarterly report was filed on May 13, 2026. SignalX displays every ALLO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ALLO filed recently?
Allogene Therapeutics, Inc. (ALLO)'s most recent 8-K was filed on June 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ALLO insider trading activity (Form 4)?
SignalX aggregates every ALLO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ALLO file with the SEC?
Allogene Therapeutics, Inc. (ALLO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ALLO filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Allogene Therapeutics, Inc. (ALLO).
What is ALLO's SEC CIK number?
Allogene Therapeutics, Inc. (ALLO)'s SEC CIK (Central Index Key) number is 1737287. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1737287 to look up all ALLO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ALLO return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Allogene Therapeutics, Inc. (ALLO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Allogene Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 51+ filings.